Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine
Status: Enrolling
Updated:  1/14/2016
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine
Status: Enrolling
Updated: 1/14/2016
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes
Calcitriol and Dexamethasone for Myelodysplastic Syndromes
Status: Enrolling
Updated:  1/14/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes
Calcitriol and Dexamethasone for Myelodysplastic Syndromes
Status: Enrolling
Updated: 1/14/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis
Status: Enrolling
Updated:  1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis
Status: Enrolling
Updated: 1/14/2016
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL)
Status: Enrolling
Updated:  1/15/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL)
Status: Enrolling
Updated: 1/15/2016
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Therapy of Early Chronic Phase CML With Gleevec
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)
Status: Enrolling
Updated:  1/19/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Therapy of Early Chronic Phase CML With Gleevec
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)
Status: Enrolling
Updated: 1/19/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Status: Enrolling
Updated:  1/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Status: Enrolling
Updated: 1/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
City of Hope National Medical Center
mi
from
Duate, CA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
City of Hope National Medical Center
mi
from
Duate, CA
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Stanford Comprehensive Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Medical College of Georgia
mi
from
Augusta, GA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Medical College of Georgia
mi
from
Augusta, GA
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated:  1/20/2016
New York Prebyterian Hospital - Weill Cornell Medical College
mi
from
New York, NY
Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis
Status: Enrolling
Updated: 1/20/2016
New York Prebyterian Hospital - Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis
Status: Enrolling
Updated:  1/21/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis
Status: Enrolling
Updated: 1/21/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Winship Cancer Center
mi
from
Atlanta, GA
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Winship Cancer Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Center
mi
from
Boston, MA
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
St. Vincent's Comprehensive Cancer Center
mi
from
New York City, NY
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
St. Vincent's Comprehensive Cancer Center
mi
from
New York City, NY
Click here to add this to my saved trials
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Colorado Health Sciences Center/Anschutz Cancer Pavilion
mi
from
Aurora, CO
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Colorado Health Sciences Center/Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Rocky Mountain Cancer Center
mi
from
Denver, CO
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Northwestern University Clinical Research Office
mi
from
Chicago, IL
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Northwestern University Clinical Research Office
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Rush University Medical Center
mi
from
Chicago, IL
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Chicago Hospital
mi
from
Chicago, IL
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Chicago Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Indiana Blood and Marrow Institute/St. Francis Hospital
mi
from
Beech Grove, IN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Indiana Blood and Marrow Institute/St. Francis Hospital
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Mayo Clinic Cancer Center
mi
from
West Rochester, MN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Mayo Clinic Cancer Center
mi
from
West Rochester, MN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Hackensack University Medical Center/Oncology Research Dept.
mi
from
Hackensack, NJ
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Hackensack University Medical Center/Oncology Research Dept.
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Duke University Hospital
mi
from
Durham, NC
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Duke University Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Oregon Health and Science University
mi
from
Portland, OR
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Emory University School of Medicine-Winship Cancer Institute
mi
from
Nashville, TN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Emory University School of Medicine-Winship Cancer Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Vanderbilt University Medical Center Clinical Trials Center
mi
from
Nashville, TN
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Vanderbilt University Medical Center Clinical Trials Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated:  1/21/2016
Novartis Investigative Site
mi
from
Cologne,
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)
A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Status: Enrolling
Updated: 1/21/2016
Novartis Investigative Site
mi
from
Cologne,
Click here to add this to my saved trials